Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Cyclic Dinucleotide-Adjuvanted Dengue Virus Nonstructural Protein 1 Induces Protective Antibody and T Cell Responses.

Espinosa DA, Beatty PR, Reiner GL, Sivick KE, Hix Glickman L, Dubensky TW Jr, Harris E.

J Immunol. 2019 Feb 15;202(4):1153-1162. doi: 10.4049/jimmunol.1801323. Epub 2019 Jan 14.

PMID:
30642979
2.

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity.

Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, Katibah GE, Kanne DB, Leong JJ, Metchette K, Bruml JR, Ndubaku CO, McKenna JM, Feng Y, Zheng L, Bender SL, Cho CY, Leong ML, van Elsas A, Dubensky TW Jr, McWhirter SM.

Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. doi: 10.1016/j.celrep.2018.11.047.

3.

STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection.

Van Dis E, Sogi KM, Rae CS, Sivick KE, Surh NH, Leong ML, Kanne DB, Metchette K, Leong JJ, Bruml JR, Chen V, Heydari K, Cadieux N, Evans T, McWhirter SM, Dubensky TW Jr, Portnoy DA, Stanley SA.

Cell Rep. 2018 May 1;23(5):1435-1447. doi: 10.1016/j.celrep.2018.04.003.

4.

TNF╬▒ and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.

Francica BJ, Ghasemzadeh A, Desbien AL, Theodros D, Sivick KE, Reiner GL, Hix Glickman L, Marciscano AE, Sharabi AB, Leong ML, McWhirter SM, Dubensky TW Jr, Pardoll DM, Drake CG.

Cancer Immunol Res. 2018 Apr;6(4):422-433. doi: 10.1158/2326-6066.CIR-17-0263. Epub 2018 Feb 22.

5.

Comment on "The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele".

Sivick KE, Surh NH, Desbien AL, Grewal EP, Katibah GE, McWhirter SM, Dubensky TW Jr.

J Immunol. 2017 Jun 1;198(11):4183-4185. doi: 10.4049/jimmunol.1700294. No abstract available.

6.

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr, Gajewski TF.

Cell Rep. 2015 May 19;11(7):1018-30. doi: 10.1016/j.celrep.2015.04.031. Epub 2015 May 7.

7.

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, Sivick KE, Zeng Q, Soares KC, Zheng L, Portnoy DA, Woodward JJ, Pardoll DM, Dubensky TW Jr, Kim Y.

Sci Transl Med. 2015 Apr 15;7(283):283ra52. doi: 10.1126/scitranslmed.aaa4306.

8.

Toll-like receptor-deficient mice reveal how innate immune signaling influences Salmonella virulence strategies.

Sivick KE, Arpaia N, Reiner GL, Lee BL, Russell BR, Barton GM.

Cell Host Microbe. 2014 Feb 12;15(2):203-13. doi: 10.1016/j.chom.2014.01.013.

9.

TLR signaling is required for Salmonella typhimurium virulence.

Arpaia N, Godec J, Lau L, Sivick KE, McLaughlin LM, Jones MB, Dracheva T, Peterson SN, Monack DM, Barton GM.

Cell. 2011 Mar 4;144(5):675-88. doi: 10.1016/j.cell.2011.01.031.

10.

The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection.

Sivick KE, Schaller MA, Smith SN, Mobley HL.

J Immunol. 2010 Feb 15;184(4):2065-75. doi: 10.4049/jimmunol.0902386. Epub 2010 Jan 18.

11.

Waging war against uropathogenic Escherichia coli: winning back the urinary tract.

Sivick KE, Mobley HL.

Infect Immun. 2010 Feb;78(2):568-85. doi: 10.1128/IAI.01000-09. Epub 2009 Nov 16. Review.

12.

Mucosal immunization with iron receptor antigens protects against urinary tract infection.

Alteri CJ, Hagan EC, Sivick KE, Smith SN, Mobley HL.

PLoS Pathog. 2009 Sep;5(9):e1000586. doi: 10.1371/journal.ppat.1000586. Epub 2009 Sep 18.

13.

An "omics" approach to uropathogenic Escherichia coli vaccinology.

Sivick KE, Mobley HL.

Trends Microbiol. 2009 Oct;17(10):431-2. doi: 10.1016/j.tim.2009.07.003. Epub 2009 Sep 14. No abstract available.

14.

Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity.

Crimmins GT, Herskovits AA, Rehder K, Sivick KE, Lauer P, Dubensky TW Jr, Portnoy DA.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10191-6. doi: 10.1073/pnas.0804170105. Epub 2008 Jul 16.

15.

Protease activity, secretion, cell entry, cytotoxicity, and cellular targets of secreted autotransporter toxin of uropathogenic Escherichia coli.

Maroncle NM, Sivick KE, Brady R, Stokes FE, Mobley HL.

Infect Immun. 2006 Nov;74(11):6124-34. Epub 2006 Sep 5.

Supplemental Content

Loading ...
Support Center